



Post Authorisation Assessments

For details of post authorisation assessments prior to 1st January 2021,
please refer to the [EMA](#) website.

Frontpro 28 mg Chewable Tablets for Dogs >4–10 kg Vm 04491/5011

•	11 January 2024	Unlimited renewal
•	13 October 2023	Addition of an alternative site responsible for manufacturing of the finished product. Editorial changes in section 3.1.2 are also included.
•	22 August 2023	Addition of a new supplier of a starting material used in the manufacturing process of the active substance. Addition of a new supplier of a starting material used in the manufacturing process of the active substance. Addition of a new supplier of a starting material used in the manufacturing process of the active substance.
•	06 June 2023	Change in batch size for intermediate used in the manufacturing process of the active substance.
•	13 April 2023	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV).
•	23 August 2022	Change in name of manufacturer of the finished product.
•	25 April 2022	Increase in batch size of the active substance.
•	25 April 2022	Change in composition of the immediate packaging for the active substance.
•	15 February 2022	Deletion of a supplier of packaging components or devices.
•	02 September 2021	Change in shape or dimensions of the container or closure (immediate packaging). Minor change in the manufacturing process of the finished product. Deletion of a non-significant specification parameter of an excipient.
•	25 March 2021	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS.